U.S. Markets open in 3 hrs 11 mins

Janux Therapeutics, Inc. (JANX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.41-2.10 (-6.88%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close30.51
Open30.21
Bid0.00 x 800
Ask0.00 x 800
Day's Range28.41 - 30.84
52 Week Range16.32 - 37.99
Volume497,220
Avg. Volume362,173
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
    Business Wire

    Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer

    SAN DIEGO, July 19, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Shahram Salek-Ardakani, Ph.D., as Chief Scientific Officer. Dr. Salek-Ardakani will lead the scientific advancement of Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to expand Janux’s pipeline of next-generation T cell engager immunotherapies. Dr. Salek-Ardakani joins Janux from

  • Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    Business Wire

    Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    LA JOLLA, Calif., Jun 15, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previously announced initial public offering of 13,110,000 shares of its common stock, which includes 1,710,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $17.00 per share. Including the option exercise, the ag